JNJ-7777120

Chemical compound
JNJ-7777120
Skeletal formula of JNJ-7777120
Ball-and-stick model of the JNJ-7777120 molecule
Clinical data
Other names1-[(5-chloro-1H-indol-2-yl)carbonyl]-4-methylpiperazine
Identifiers
  • 5-chloro-2-[(4-methylpiperazin-1-yl)carbonyl]-1H-indole
CAS Number
  • 459168-41-3 checkY
PubChem CID
  • 4908365
IUPHAR/BPS
  • 1278
ChemSpider
  • 4090750 ☒N
UNII
  • 4H1AU2V37X
ChEMBL
  • ChEMBL129198 ☒N
CompTox Dashboard (EPA)
  • DTXSID20963461 Edit this at Wikidata
ECHA InfoCard100.164.683 Edit this at Wikidata
Chemical and physical data
FormulaC14H16ClN3O
Molar mass277.75 g·mol−1
3D model (JSmol)
  • Interactive image
  • C3CN(C)CCN3C(=O)c(cc1c2)[nH]c1ccc2Cl
InChI
  • InChI=1S/C14H16ClN3O/c1-17-4-6-18(7-5-17)14(19)13-9-10-8-11(15)2-3-12(10)16-13/h2-3,8-9,16H,4-7H2,1H3 ☒N
  • Key:HUQJRYMLJBBEDO-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

JNJ-7777120 was a drug being developed by Johnson & Johnson Pharmaceutical Research & Development which acts as a potent and selective antagonist at the histamine H4 receptor.[1] It has anti-inflammatory effects,[2] and has been demonstrated to be superior to traditional (H1) antihistamines in the treatment of pruritus (itching).[3] The drug was abandoned because of its short in vivo half-life and hypoadrenocorticism toxicity in rats and dogs, that prevented advancing it into clinical studies.[4]

See also

References

  1. ^ Jiang W, Lim HD, Zhang M, et al. (July 2008). "Cloning and pharmacological characterization of the dog histamine H(4) receptor". Eur. J. Pharmacol. 592 (1–3): 26–32. doi:10.1016/j.ejphar.2008.06.095. PMID 18639542.
  2. ^ Thurmond RL, Desai PJ, Dunford PJ, Fung-Leung WP, Hofstra CL, Jiang W, Nguyen S, Riley JP, Sun S, Williams KN, Edwards JP, Karlsson L (Apr 2004). "A potent and selective histamine H4 receptor antagonist with anti-inflammatory properties". Journal of Pharmacology and Experimental Therapeutics. 309 (1): 404–13. doi:10.1124/jpet.103.061754. PMID 14722321. S2CID 8396875.
  3. ^ Dunford PJ, Williams KN, Desai PJ, Karlsson L, McQueen D, Thurmond RL (Jan 2007). "Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritus". Journal of Allergy and Clinical Immunology. 119 (1): 176–83. doi:10.1016/j.jaci.2006.08.034. PMID 17208599.
  4. ^ Thurmond RL, Venable J, Savall B, La D, Snook S, Dunford PJ, Edwards JP (2017). "Clinical Development of Histamine H4 Receptor Antagonists". Histamine and Histamine Receptors in Health and Disease. Handbook of Experimental Pharmacology. Vol. 241. pp. 301–320. doi:10.1007/164_2016_130. ISBN 978-3-319-58192-7. PMID 28233185.
  • v
  • t
  • e
H1
Agonists
Antagonists
  • Unknown/unsorted: Azanator
  • Belarizine
  • Elbanizine
  • Flotrenizine
  • GSK1004723
  • Napactadine
  • Tagorizine
  • Trelnarizine
  • Trenizine
H2
Agonists
Antagonists
H3
Agonists
Antagonists
H4
Agonists
Antagonists
See also
Receptor/signaling modulators
Monoamine metabolism modulators
Monoamine reuptake inhibitors
  • v
  • t
  • e
Simple piperazines
(no additional rings)
Phenylpiperazines
Benzylpiperazines
Diphenylalkylpiperazines
(benzhydrylalkylpiperazines)
Pyrimidinylpiperazines
Pyridinylpiperazines
Benzo(iso)thiazolylpiperazines
Tricyclics
(piperazine attached via side chain)
Others/Uncategorized


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e